首页 正文

Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma

{{output}}
Plasmacytoid urothelial carcinoma (PUC) is a rare and aggressive histologic subtype of urothelial carcinoma with no well-established treatment. Recently, the combination of pembrolizumab and enfortumab vedotin has become the standard of care for locally advanc... ...